OpGen, Inc. (NASDAQ:OPGN) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On November 16, 2016, OpGen, Inc. (the “Company”) is first
making a corporate presentation that provides a current overview
about the Company. The information provided during such corporate
presentation is attached as an exhibit to this Form 8-K.
The information in this Form 8-K and the Exhibit attached hereto
shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, except as shall be expressly
set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit |
Description
|
99.1 |
Corporation Presentation of OpGen, Inc., November 2016
|
About OpGen, Inc. (NASDAQ:OPGN)
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name. OpGen, Inc. (NASDAQ:OPGN) Recent Trading Information
OpGen, Inc. (NASDAQ:OPGN) closed its last trading session up +0.05 at 1.16 with 129,541 shares trading hands.
